
AI May Cut Drug Development Time, Says Biocon's Kiran Mazumdar-Shaw
What Happened?
Kiran Mazumdar-Shaw of Biocon stated that AI could reduce drug development time from five to seven years to just one or two years. She emphasized AI's role in precision medicine during the Bengaluru Tech Summit 2026.
Key points
- AI can potentially compress drug development timelines from five to seven years to one or two years.
- Shaw highlighted the importance of AI in selecting the right patients for clinical trials.
- She mentioned the need for regulations to keep pace with accelerated drug discovery.
- AI is expected to simplify complex biological systems and enhance drug innovation.
- Discussions are ongoing in Karnataka to create a 'regulatory sandbox' for faster validation of concepts.
Key insights
- Accelerating drug development through AI may lead to faster patient access to innovative treatments.
- The integration of AI in clinical trials could improve the efficiency of patient selection.
- Karnataka's initiative for a regulatory sandbox may set a precedent for other regions in drug innovation.
Why it matters
The advancements in AI could significantly accelerate drug development, impacting patient access to new therapies.
Tags
Entities
Source
Business Standard
